Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market

view original post

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, Novo Nordisk’s Ozempic and Wegovy are losing market share to the American …